Cargando…
Monensin suppresses cell proliferation and invasion in ovarian cancer by enhancing MEK1 SUMOylation
Ovarian cancer is the most lethal gynecologic malignancy, and is usually diagnosed at an advanced stage. Most patients relapse within 12-24 months and die from progressive chemotherapy-resistant diseases. Significant progress has been made in developing new targeted therapies for human cancer, inclu...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506924/ https://www.ncbi.nlm.nih.gov/pubmed/34650638 http://dx.doi.org/10.3892/etm.2021.10826 |